Full-Time

Senior Director – GRA Development & Product Strategy Team Lead

Bone & Mineral

Kyowa Kirin

Kyowa Kirin

1,001-5,000 employees

Global specialty pharma leveraging fermentation and antibodies

No salary listed

Princeton, NJ, USA

Hybrid

Hybrid role with on-site presence at Princeton, NJ.

Category
Business & Strategy (2)
,
Requirements
  • Bachelor’s degree in life sciences, pharmacy, or a related scientific discipline required.
  • Minimum 12+ years extensive regulatory affairs experience within the pharmaceutical, biotechnology, or related industry, including global development and lifecycle management, with a focus on bone and mineral disease areas.
  • Proven leadership experience, including managing and developing high-performing regulatory teams and/or leading through other leaders (e.g., GRLs).
  • Demonstrated success in developing and executing global regulatory strategies across multiple regions and product stages (development through post-approval).
  • Significant experience interacting with health authorities, including leading regulatory agency meetings and negotiations.
  • Cross-functional leadership experience, with a strong track record of influencing stakeholders and driving alignment across complex, matrixed organizations.
  • Experience supporting business development activities, including regulatory due diligence for in-licensing, out-licensing, or partnerships.
  • Strong collaboration across cross-functional teams including regulatory affairs, government affairs, clinical, legal, and R&D.
  • Deep knowledge of global regulatory frameworks and guidelines, including major markets (e.g., FDA, EMA, ICH, PMDA) and their application to drug development and lifecycle management.
  • Expertise in regulatory submissions and approvals, including INDs/CTAs, NDAs/BLAs/MAAs, and post-approval variations.
  • Strong understanding of global labeling requirements, including development and maintenance of Company Core Data Sheets (CCDS).
  • Advanced regulatory strategy development and risk management skills, with the ability to anticipate challenges and drive solutions.
  • Familiarity with GxP requirements and regulatory compliance standards, including inspection and audit readiness.
  • Proficiency in regulatory systems, tools, and document management platforms used for submissions, tracking, and compliance.
  • Strong organizational and project management skills with the ability to manage multiple initiatives simultaneously.
  • Exceptional communication and influencing skills, with the ability to clearly articulate complex regulatory strategies, risks, and requirements to diverse audiences, including health authorities, senior leadership, and cross-functional teams, to drive alignment and informed decision-making.
  • Strong proficiency MS Office Suite.
Responsibilities
  • Define and drive global regulatory strategies for all products within the assigned disease area, ensuring alignment with enterprise objectives and maximizing product value.
  • Lead and develop a team of Global Regulatory Leads (GRLs), setting direction, building capabilities, and fostering a high-performance, accountable culture.
  • Shape and integrate regulatory strategy into global product development and lifecycle plans in close partnership with cross-functional stakeholders.
  • Oversee and ensure execution of regulatory strategies, including global submissions, approvals, and post-approval activities across assigned products and projects.
  • Direct and represent the organization in interactions with health authorities, including leading negotiations and overseeing agency meeting strategy and execution.
  • Guide and approve global regulatory submission plans, including marketing applications, labeling (e.g., CCDS), and key lifecycle deliverables.
  • Manage and coordinate regulatory activities, timelines, and deliverables across internal teams and external partners, ensuring alignment and on-time execution.
  • Ensure compliance with global regulatory requirements, internal policies, and GxP standards, including support for inspections, audits, and governance processes.
  • Assess and communicate regulatory risks, emerging trends, and competitive intelligence, escalating issues and recommending mitigation strategies as appropriate.
  • Drive operational excellence by leading process improvements, standardization efforts (e.g., SOPs/WIs), and adoption of best practices across Regulatory Affairs.
  • Oversee external partnerships and due diligence activities, including vendor selection, alliance management, and regulatory support for business development transactions.
  • Contribute to organizational leadership, including participation in RA Functional Teams (RAFTs), budget oversight, and fostering collaboration across Regulatory Affairs and the broader organization.
  • Establish and maintain global labeling strategy, including oversight of Company Core Data Sheet (CCDS) development and alignment with regional labeling requirements.
  • Allocate and optimize regulatory resources across the portfolio, ensuring effective prioritization and support for key business objectives.
  • Recruit and build organizational capability by leading talent acquisition, succession planning, and ongoing training initiatives within the regulatory function.
  • Ensure alignment with Vision 2030, company Core Values, Kabegoe Principles, and the Global Regulatory Affairs Vision.
Desired Qualifications
  • Advanced degree (e.g., Master of Science, Doctor of Philosophy, Doctor of Pharmacy, Master of Business Administration) is preferred but not required; relevant industry experience may be considered in lieu of advanced education.

Kyowa Kirin is a global specialty pharmaceutical company that develops medicines using fermentation and antibody technologies. Its products target areas like nephrology, oncology, and immunology, with therapies built from biologics and other drug modalities. The company emerged from a merger between Kyowa Hakko Kogyo and Kirin Pharma, combining Kyowa’s fermentation and microbiology expertise with Kirin’s pharma resources to create a worldwide focus on specialty drugs. Unlike broader drug companies, Kyowa Kirin concentrates on a defined set of indications and runs a research-and-development-led business that aims to deliver innovative treatments for patients in need.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Tokyo, Japan

Founded

1885

Simplify Jobs

Simplify's Take

What believers are saying

  • Libmeldy commercialization in MLD expands rare disease revenue streams globally.
  • Orchard pipeline programs in MPS, FTD, Crohn's disease address high unmet needs.
  • North Carolina manufacturing capacity supports cell and gene therapy market growth.

What critics are saying

  • Libmeldy reimbursement denial in UK, Germany, US collapses primary revenue driver.
  • Orchard pipeline failures in Phase 2/3 trials eliminate $478M acquisition rationale.
  • Gene therapy manufacturing delays at Sanford facility constrain supply and revenue ramp.

What makes Kyowa Kirin unique

  • 75+ years fermentation expertise underpins proprietary antibody and gene therapy platforms.
  • Orchard Therapeutics acquisition adds Libmeldy gene therapy for rare genetic diseases.
  • $530M Sanford biologics facility enables scaled manufacturing of advanced cell therapies.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Kyowa Kirin who can refer or advise you

Benefits

401(k) Company Match

Paid Vacation

Paid Sick Leave

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Hybrid Work Options

Pet Insurance

Tuition Assistance

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

-1%

2 year growth

-1%
Benzinga
Dec 15th, 2025
Link Cell Therapies raises $92M to advance CAR-T cancer treatments for solid and liquid tumors

Link Cell Therapies has emerged from stealth with $60 million in Series A funding led by Johnson & Johnson Innovation – JJDC, bringing total capital raised to $92 million. The South San Francisco–based oncology company is developing CAR-T therapies for solid and liquid tumours using proprietary logic-gating technology. The platform enables safe targeting of multiple antigens co-expressed on cancer cells whilst sparing healthy tissue. Co-founded by Dr Robbie Majzner and Dr Crystal Mackall at Stanford University in 2022, Link's lead programme, LNK001 for renal cell carcinoma, is on track for an IND application and Phase I trial in 2026. The Series A round included participation from founding investors Samsara BioCapital and Sheatree Capital, alongside new backers Bristol Myers Squibb, Kyowa Kirin and Wing Venture Capital.

FinSMEs
Mar 4th, 2025
Garuda Therapeutics Closes $50M Series A-1 Financing

Garuda Therapeutics, a Cambridge, MA-based hematopoietic stem cell (HSC) therapies company, raised $50M in Series A-1 funding

Cimeio Therapeutics
Dec 10th, 2024
Cimeio Therapeutics Announces Partnership with Kyowa Kirin to Develop Novel Cell Therapies

The partnership combines Cimeio's proprietary Shielded Cell and Immunotherapy (SCIP) platform with Kyowa Kirin's expertise in cellular therapies and underscores both companies' commitment to using emerging cell and gene therapy technologies to develop new ways to treat patients.

Business North Carolina
Nov 27th, 2024
Op/ed: Biotech's role in North Carolina's job-creation success

Kyowa Kirin, a Japanese global specialty pharmaceutical company, plans to invest more than $200 million in Sanford to build its first pharmaceutical manufacturing complex in North America, adding more than 100 new jobs.

World Pharmaceutical Frontiers
Jun 11th, 2024
Kyowa Kirin to establish new $530m biologics manufacturing plant in US

Japan-based Kyowa Kirin has unveiled its plans to invest $530m to build a new advanced biologics manufacturing facility in Sanford in the American state of North Carolina.